BG64600B1 - Кетолиди от класа на 15-членни лактами с антибактериална активност - Google Patents

Кетолиди от класа на 15-членни лактами с антибактериална активност Download PDF

Info

Publication number: BG64600B1
Authority: BG; Bulgaria
Prior art keywords: group; hydrogen; compound; formula; ketone
Prior art date: 1998-04-06

Application number

BG104913A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG104913A (en

Inventor

Gorjana Lazarevski

Gabrijela Kobrehel

Zeljko Kelneric

Original Assignee

Pliva, Farmaceutska Industrija, Dionicko Drustvo

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-06

Filing date

2000-11-06

Publication date

2005-08-31

2000-11-06 Application filed by Pliva, Farmaceutska Industrija, Dionicko Drustvo filed Critical Pliva, Farmaceutska Industrija, Dionicko Drustvo

2001-08-31 Publication of BG104913A publication Critical patent/BG104913A/xx

2005-08-31 Publication of BG64600B1 publication Critical patent/BG64600B1/bg

Links

230000000844 anti-bacterial effect Effects 0.000 title description 4
239000003835 ketolide antibiotic agent Substances 0.000 title description 3
150000003951 lactams Chemical class 0.000 title description 3
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 31
239000001257 hydrogen Substances 0.000 claims abstract description 31
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 18
238000000034 method Methods 0.000 claims abstract description 18
-1 L-cladinosyl group Chemical group 0.000 claims abstract description 16
150000003839 salts Chemical class 0.000 claims abstract description 12
150000007522 mineralic acids Chemical class 0.000 claims abstract description 9
150000007524 organic acids Chemical class 0.000 claims abstract description 9
238000002360 preparation method Methods 0.000 claims abstract description 9
125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims abstract description 8
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
235000005985 organic acids Nutrition 0.000 claims abstract description 5
208000035143 Bacterial infection Diseases 0.000 claims abstract description 4
208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 4
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 36
AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims description 31
229960002626 clarithromycin Drugs 0.000 claims description 30
150000001875 compounds Chemical class 0.000 claims description 28
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 23
150000002576 ketones Chemical class 0.000 claims description 23
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 22
238000006243 chemical reaction Methods 0.000 claims description 15
239000002904 solvent Substances 0.000 claims description 15
229910052760 oxygen Inorganic materials 0.000 claims description 14
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 11
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 11
239000000908 ammonium hydroxide Substances 0.000 claims description 11
150000002923 oximes Chemical class 0.000 claims description 11
229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 11
235000017557 sodium bicarbonate Nutrition 0.000 claims description 11
239000000203 mixture Substances 0.000 claims description 9
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
239000000741 silica gel Substances 0.000 claims description 8
229910002027 silica gel Inorganic materials 0.000 claims description 8
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 claims description 7
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
150000002431 hydrogen Chemical class 0.000 claims description 6
150000007529 inorganic bases Chemical class 0.000 claims description 6
239000003960 organic solvent Substances 0.000 claims description 6
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 5
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 5
150000007530 organic bases Chemical class 0.000 claims description 5
238000006237 Beckmann rearrangement reaction Methods 0.000 claims description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
230000003647 oxidation Effects 0.000 claims description 4
238000007254 oxidation reaction Methods 0.000 claims description 4
NRTYMEPCRDJMPZ-UHFFFAOYSA-N pyridine;2,2,2-trifluoroacetic acid Chemical compound C1=CC=NC=C1.OC(=O)C(F)(F)F NRTYMEPCRDJMPZ-UHFFFAOYSA-N 0.000 claims description 4
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 3
238000005917 acylation reaction Methods 0.000 claims description 3
125000004432 carbon atom Chemical group C* 0.000 claims description 3
239000003054 catalyst Substances 0.000 claims description 3
229910052757 nitrogen Inorganic materials 0.000 claims description 3
OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 claims description 3
238000000926 separation method Methods 0.000 claims description 3
150000001298 alcohols Chemical class 0.000 claims description 2
241001465754 Metazoa Species 0.000 claims 2
239000003937 drug carrier Substances 0.000 claims 2
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims 1
150000001241 acetals Chemical class 0.000 claims 1
150000008064 anhydrides Chemical class 0.000 claims 1
150000001735 carboxylic acids Chemical class 0.000 claims 1
230000020176 deacylation Effects 0.000 claims 1
238000005947 deacylation reaction Methods 0.000 claims 1
239000011877 solvent mixture Substances 0.000 claims 1
238000003797 solvolysis reaction Methods 0.000 claims 1
239000000543 intermediate Substances 0.000 abstract description 5
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
125000000468 ketone group Chemical group 0.000 abstract 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
239000000243 solution Substances 0.000 description 14
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 13
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 12
230000008707 rearrangement Effects 0.000 description 12
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
229960003276 erythromycin Drugs 0.000 description 10
229910052740 iodine Inorganic materials 0.000 description 9
239000000047 product Substances 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
238000005481 NMR spectroscopy Methods 0.000 description 8
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical group [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
239000011541 reaction mixture Substances 0.000 description 8
229930006677 Erythromycin A Natural products 0.000 description 7
239000000284 extract Substances 0.000 description 7
239000003120 macrolide antibiotic agent Substances 0.000 description 7
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
230000002378 acidificating effect Effects 0.000 description 6
238000004587 chromatography analysis Methods 0.000 description 6
229910001510 metal chloride Inorganic materials 0.000 description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
238000003756 stirring Methods 0.000 description 6
MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 5
229960004099 azithromycin Drugs 0.000 description 5
239000002585 base Substances 0.000 description 5
238000001704 evaporation Methods 0.000 description 5
230000008020 evaporation Effects 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
239000010410 layer Substances 0.000 description 5
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 4
PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
230000000694 effects Effects 0.000 description 4
GWZLAOIJICWIRB-UHFFFAOYSA-N ethyl acetate;n-ethylethanamine;hexane Chemical compound CCNCC.CCCCCC.CCOC(C)=O GWZLAOIJICWIRB-UHFFFAOYSA-N 0.000 description 4
238000000605 extraction Methods 0.000 description 4
PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 4
238000007069 methylation reaction Methods 0.000 description 4
229910000027 potassium carbonate Inorganic materials 0.000 description 4
238000010992 reflux Methods 0.000 description 4
229910000029 sodium carbonate Inorganic materials 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
239000012043 crude product Substances 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
230000007935 neutral effect Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
UXDNUPFGRUGPKK-XBWOTNPQSA-N (2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-11-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,8,10,12,14-hexamethyl-1-oxa-6-azacyclopentadecane-7,15-d Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)NC(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 UXDNUPFGRUGPKK-XBWOTNPQSA-N 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
ZOYWWAGVGBSJDL-UHFFFAOYSA-N D-desosamine Natural products CC1CC(N(C)C)C(O)C(O)O1 ZOYWWAGVGBSJDL-UHFFFAOYSA-N 0.000 description 2
241000589989 Helicobacter Species 0.000 description 2
241000589248 Legionella Species 0.000 description 2
208000007764 Legionnaires' Disease Diseases 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
230000010933 acylation Effects 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
239000004599 antimicrobial Substances 0.000 description 2
CELPHAGZKFMOMR-UHFFFAOYSA-N azanium;dichloromethane;methanol;hydroxide Chemical compound [NH4+].[OH-].OC.ClCCl CELPHAGZKFMOMR-UHFFFAOYSA-N 0.000 description 2
MLWPJXZKQOPTKZ-UHFFFAOYSA-N benzenesulfonyl benzenesulfonate Chemical class C=1C=CC=CC=1S(=O)(=O)OS(=O)(=O)C1=CC=CC=C1 MLWPJXZKQOPTKZ-UHFFFAOYSA-N 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
VTJCSBJRQLZNHE-CSMHCCOUSA-N desosamine Chemical compound C[C@@H](O)C[C@H](N(C)C)[C@@H](O)C=O VTJCSBJRQLZNHE-CSMHCCOUSA-N 0.000 description 2
238000001914 filtration Methods 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
230000011987 methylation Effects 0.000 description 2
244000005700 microbiome Species 0.000 description 2
ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
238000006265 spirocyclization reaction Methods 0.000 description 2
238000006277 sulfonation reaction Methods 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
RVHOBHMAPRVOLO-UHFFFAOYSA-N 2-ethylbutanedioic acid Chemical compound CCC(C(O)=O)CC(O)=O RVHOBHMAPRVOLO-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
241000589874 Campylobacter fetus Species 0.000 description 1
241000589875 Campylobacter jejuni Species 0.000 description 1
241000606161 Chlamydia Species 0.000 description 1
241000194033 Enterococcus Species 0.000 description 1
241001360526 Escherichia coli ATCC 25922 Species 0.000 description 1
241000192125 Firmicutes Species 0.000 description 1
206010048461 Genital infection Diseases 0.000 description 1
241000606768 Haemophilus influenzae Species 0.000 description 1
101001081176 Homo sapiens Hyaluronan mediated motility receptor Proteins 0.000 description 1
101000632319 Homo sapiens Septin-7 Proteins 0.000 description 1
102100027735 Hyaluronan mediated motility receptor Human genes 0.000 description 1
241000186779 Listeria monocytogenes Species 0.000 description 1
239000012359 Methanesulfonyl chloride Substances 0.000 description 1
241000588655 Moraxella catarrhalis Species 0.000 description 1
101100518501 Mus musculus Spp1 gene Proteins 0.000 description 1
241000204031 Mycoplasma Species 0.000 description 1
241000588769 Proteus <enterobacteria> Species 0.000 description 1
241000588770 Proteus mirabilis Species 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
102100027981 Septin-7 Human genes 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
241000193996 Streptococcus pyogenes Species 0.000 description 1
108010015795 Streptogramin B Proteins 0.000 description 1
241000607734 Yersinia <bacteria> Species 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
229910001854 alkali hydroxide Inorganic materials 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
229940040526 anhydrous sodium acetate Drugs 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
150000003857 carboxamides Chemical class 0.000 description 1
150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
244000144992 flock Species 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
229940047650 haemophilus influenzae Drugs 0.000 description 1
VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
238000011005 laboratory method Methods 0.000 description 1
150000002596 lactones Chemical group 0.000 description 1
229940041033 macrolides Drugs 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
238000006140 methanolysis reaction Methods 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
238000002493 microarray Methods 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
244000052769 pathogen Species 0.000 description 1
210000001539 phagocyte Anatomy 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
229920000137 polyphosphoric acid Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
YGXCETJZBDTKRY-DZCVGBHJSA-N pristinamycin IA Chemical compound N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2CCC(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O YGXCETJZBDTKRY-DZCVGBHJSA-N 0.000 description 1
239000003586 protic polar solvent Substances 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
230000007723 transport mechanism Effects 0.000 description 1
IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Hydrogenated Pyridines (AREA)

BG104913A 1998-04-06 2000-11-06 Кетолиди от класа на 15-членни лактами с антибактериална активност BG64600B1 (bg)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
HR980189A HRP980189B1 (en)	1998-04-06	1998-04-06	Novel 15-membered lactams ketolides

Publications (2)

Publication Number	Publication Date
BG104913A BG104913A (en)	2001-08-31
BG64600B1 true BG64600B1 (bg)	2005-08-31

Family

ID=10946724

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG104913A BG64600B1 (bg)	1998-04-06	2000-11-06	Кетолиди от класа на 15-членни лактами с антибактериална активност

Country Status (26)

Country	Link
US (1)	US6110965A (et)
EP (1)	EP1070077B1 (et)
JP (1)	JP2002510701A (et)
KR (1)	KR100600463B1 (et)
CN (1)	CN1141312C (et)
AR (1)	AR019261A1 (et)
AT (1)	ATE241638T1 (et)
AU (1)	AU3046499A (et)
BG (1)	BG64600B1 (et)
BR (1)	BR9910115A (et)
CA (1)	CA2327775C (et)
DE (1)	DE69908338T2 (et)
DK (1)	DK1070077T3 (et)
EE (1)	EE04283B1 (et)
ES (1)	ES2200512T3 (et)
HR (1)	HRP980189B1 (et)
HU (1)	HUP0101817A3 (et)
IL (2)	IL138837A0 (et)
NO (1)	NO317982B1 (et)
PL (1)	PL193742B1 (et)
PT (1)	PT1070077E (et)
RU (1)	RU2211222C2 (et)
SI (1)	SI1070077T1 (et)
SK (1)	SK284169B6 (et)
UA (1)	UA70941C2 (et)
WO (1)	WO1999051616A1 (et)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP990116B1 (en) *	1999-04-20	2007-10-31	GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o.	NOVEL 8a AND 9a- 15-MEMBERED LACTAMES
MXPA02009587A (es) *	2000-03-28	2003-05-14	Biochemie Gmbh	Particulas granuladas con sabor enmascarado.
GB0025688D0 (en) *	2000-10-19	2000-12-06	Glaxo Group Ltd	Macrolides
GEP20063812B (en) *	2001-08-21	2006-05-10	Pfizer Prod Inc	Single dose azithromycin for treating respirator infections
EP1483277A4 (en)	2002-02-15	2007-10-03	Merckle Gmbh	CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS, METHODS OF PREPARATION AND USE, AND FORMULATION AND PHARMACEUTICAL APPLICATIONS
WO2003070254A1 (en)	2002-02-15	2003-08-28	Sympore Gmbh	Antibiotic conjugates
WO2003070173A2 (en)	2002-02-15	2003-08-28	Sympore Gmbh	Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
JP4530851B2 (ja)	2002-07-08	2010-08-25	グラクソスミスクライン・イストラジヴァッキ・センタル・ザグレブ・ドルズバ・ゼー・オメイェノ・オドゴヴォルノスティオ	ステロイド／非ステロイド抗炎症活性分子、抗新生物活性分子および抗ウイルス活性分子用担体としての新規な化合物、組成物
AU2003255851B2 (en)	2002-07-08	2009-07-23	Glaxosmithkline Istrazivacki Centar Zagreb D.O.O.	New compounds, compositions and methods for treatment of inflammatory diseases and conditions
HRP20020779A2 (en)	2002-09-27	2005-02-28	Pliva-Istra�iva�ki institut d.o.o.	NEW 3-DECLADINOSYL DERIVATIVES OF 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERYTHROMICIN A 9a, 11-CYCLIC CARBAMATES
US7435805B2 (en)	2003-05-30	2008-10-14	Glaxpsmithkline Istrazivacki	O-alkyl macrolide and azalide derivatives and regioselective process for their preparation
US7276487B2 (en) *	2003-09-23	2007-10-02	Enanta Pharmaceuticals, Inc.	9a, 11-3C-bicyclic 9a-azalide derivatives
WO2006087644A2 (en)	2005-01-13	2006-08-24	Glaxosmithkline Istrazivacki Centar Zagreb D.O.O.	Macrolides with anti-inflammatory activity
WO2006120541A1 (en)	2005-05-10	2006-11-16	Glaxosmithkline Istrazivacki Centar Zagreb D.O.O.	Ether linked macrolides useful for the treatment of microbial infections
JP5126685B2 (ja) *	2006-05-01	2013-01-23	大正製薬株式会社	マクロライド誘導体
WO2009007988A1 (en) *	2007-07-11	2009-01-15	Alembic Limited	Process for the preparation of 6-o-methylerythromycin a 9-oxime
WO2010086349A1 (en)	2009-01-30	2010-08-05	Glaxosmithkline Istrazivacki Centar Zagreb D.O.O.	Anti-inflammatory macrolide
WO2011131749A1 (en)	2010-04-23	2011-10-27	Glaxo Group Limited	New 14 and 15 membered macrolides for the treatment of neutrophil dominated inflammatory diseases
PT2673285T (pt) *	2010-12-09	2017-10-19	Wockhardt Ltd	Resumo
CA3120148A1 (en) *	2018-11-19	2020-05-28	Zikani Therapeutics, Inc.	C10-alkylene substituted 13-membered macrolides and uses thereof
US20230250124A1 (en) *	2019-10-29	2023-08-10	Hikal Limited	Substantially pure clarithromycin 9-oxime and its preparation thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4328334A (en) *	1979-04-02	1982-05-04	Pliva Pharmaceutical And Chemical Works	11-Aza-10-deoxo-10-dihydroerythromycin A and derivatives thereof as well as a process for their preparation
US4331803A (en) *	1980-06-04	1982-05-25	Taisho Pharmaceutical Co., Ltd.	Novel erythromycin compounds
BE892357A (fr) *	1981-03-06	1982-07-01	Pliva Pharm & Chem Works	Nouveaux derives de l'erythromycine a, procede pour leur preparation et leur utilisation comme substances anti-bacteriennes
EP0507595A1 (en) *	1991-04-05	1992-10-07	Merck & Co. Inc.	8A-aza-8A-homoerythromycin lactams
FR2697524A1 (fr) *	1992-11-05	1994-05-06	Roussel Uclaf	Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
EP0596802A1 (fr) *	1992-11-05	1994-05-11	Roussel Uclaf	Nouveaux dérivés de l'érythromycine, leur procédé de préparation, leur application comme médicaments

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS61103890A (ja) *	1984-10-26	1986-05-22	Taisho Pharmaceut Co Ltd	６−０−メチルエリスロマイシンａ誘導体
US5302705A (en) *	1989-10-07	1994-04-12	Taisho Pharmaceutical Co., Ltd.	6-O-methylerythromycin a oxime derivatives
US5166967A (en) *	1990-08-27	1992-11-24	Fabian Carl E	Markers for dental x-ray film and packets for simplified film mounting
IL114589A (en) *	1990-11-21	1999-12-22	Roussel Uclaf	Intermediates for the preparation of erythromycin derivatives
US5202434A (en) *	1991-04-05	1993-04-13	Merck & Co., Inc.	8a-aza-8a-homoerythromycin lactams
EP0549040A1 (en) *	1991-12-20	1993-06-30	Merck & Co. Inc.	Methods of making 4" derivatives of 9-deoxo-8a-aza-8a-alkyl-8a-homoerythromycin A
ATE154806T1 (de) *	1993-05-19	1997-07-15	Pfizer	Zwischenprodukt für azithromycin
FR2718450B1 (fr) *	1994-04-08	1997-01-10	Roussel Uclaf	Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
RU2144541C1 (ru) *	1995-12-08	2000-01-20	Руссель Юклаф	Производные эритромицина, способ их получения, промежуточный продукт, фармацевтическая композиция

1998
- 1998-04-06 HR HR980189A patent/HRP980189B1/xx not_active IP Right Cessation
- 1998-07-31 US US09/127,764 patent/US6110965A/en not_active Expired - Lifetime
1999
- 1999-02-04 UA UA2000106059A patent/UA70941C2/uk unknown
- 1999-04-02 JP JP2000542337A patent/JP2002510701A/ja active Pending
- 1999-04-02 CN CNB998063568A patent/CN1141312C/zh not_active Expired - Fee Related
- 1999-04-02 CA CA002327775A patent/CA2327775C/en not_active Expired - Fee Related
- 1999-04-02 PT PT99911955T patent/PT1070077E/pt unknown
- 1999-04-02 RU RU2000128042/04A patent/RU2211222C2/ru not_active IP Right Cessation
- 1999-04-02 ES ES99911955T patent/ES2200512T3/es not_active Expired - Lifetime
- 1999-04-02 WO PCT/HR1999/000004 patent/WO1999051616A1/en not_active Ceased
- 1999-04-02 AT AT99911955T patent/ATE241638T1/de not_active IP Right Cessation
- 1999-04-02 EE EEP200000587A patent/EE04283B1/et not_active IP Right Cessation
- 1999-04-02 SI SI9930366T patent/SI1070077T1/xx unknown
- 1999-04-02 BR BR9910115-7A patent/BR9910115A/pt not_active Application Discontinuation
- 1999-04-02 DK DK99911955T patent/DK1070077T3/da active
- 1999-04-02 SK SK1502-2000A patent/SK284169B6/sk not_active IP Right Cessation
- 1999-04-02 DE DE69908338T patent/DE69908338T2/de not_active Expired - Lifetime
- 1999-04-02 EP EP99911955A patent/EP1070077B1/en not_active Expired - Lifetime
- 1999-04-02 IL IL13883799A patent/IL138837A0/xx not_active IP Right Cessation
- 1999-04-02 KR KR1020007011140A patent/KR100600463B1/ko not_active Expired - Fee Related
- 1999-04-02 PL PL99343441A patent/PL193742B1/pl unknown
- 1999-04-02 HU HU0101817A patent/HUP0101817A3/hu unknown
- 1999-04-02 AU AU30464/99A patent/AU3046499A/en not_active Abandoned
- 1999-04-05 AR ARP990101519A patent/AR019261A1/es active IP Right Grant
2000
- 2000-10-03 IL IL138837A patent/IL138837A/en unknown
- 2000-10-05 NO NO20005015A patent/NO317982B1/no unknown
- 2000-11-06 BG BG104913A patent/BG64600B1/bg unknown

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4328334A (en) *	1979-04-02	1982-05-04	Pliva Pharmaceutical And Chemical Works	11-Aza-10-deoxo-10-dihydroerythromycin A and derivatives thereof as well as a process for their preparation
US4331803A (en) *	1980-06-04	1982-05-25	Taisho Pharmaceutical Co., Ltd.	Novel erythromycin compounds
BE892357A (fr) *	1981-03-06	1982-07-01	Pliva Pharm & Chem Works	Nouveaux derives de l'erythromycine a, procede pour leur preparation et leur utilisation comme substances anti-bacteriennes
EP0507595A1 (en) *	1991-04-05	1992-10-07	Merck & Co. Inc.	8A-aza-8A-homoerythromycin lactams
FR2697524A1 (fr) *	1992-11-05	1994-05-06	Roussel Uclaf	Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
EP0596802A1 (fr) *	1992-11-05	1994-05-11	Roussel Uclaf	Nouveaux dérivés de l'érythromycine, leur procédé de préparation, leur application comme médicaments

Also Published As

Publication number	Publication date
BR9910115A (pt)	2000-12-26
UA70941C2 (uk)	2004-11-15
US6110965A (en)	2000-08-29
CA2327775C (en)	2007-08-07
NO317982B1 (no)	2005-01-17
NO20005015D0 (no)	2000-10-05
EP1070077A1 (en)	2001-01-24
HUP0101817A3 (en)	2003-07-28
CN1301268A (zh)	2001-06-27
HRP980189A2 (en)	2000-12-31
BG104913A (en)	2001-08-31
EE200000587A (et)	2002-04-15
WO1999051616A1 (en)	1999-10-14
SI1070077T1 (en)	2004-02-29
DK1070077T3 (da)	2003-09-22
IL138837A (en)	2006-10-05
KR100600463B1 (ko)	2006-07-13
DE69908338T2 (de)	2004-04-08
PL193742B1 (pl)	2007-03-30
JP2002510701A (ja)	2002-04-09
HK1036457A1 (en)	2002-01-04
IL138837A0 (en)	2001-10-31
DE69908338D1 (de)	2003-07-03
EE04283B1 (et)	2004-04-15
EP1070077B1 (en)	2003-05-28
AR019261A1 (es)	2002-02-13
HUP0101817A2 (hu)	2001-11-28
CN1141312C (zh)	2004-03-10
ES2200512T3 (es)	2004-03-01
AU3046499A (en)	1999-10-25
ATE241638T1 (de)	2003-06-15
KR20010034754A (ko)	2001-04-25
HRP980189B1 (en)	2004-04-30
RU2211222C2 (ru)	2003-08-27
NO20005015L (no)	2000-12-04
SK284169B6 (sk)	2004-10-05
PT1070077E (pt)	2003-10-31
PL343441A1 (en)	2001-08-13
SK15022000A3 (sk)	2001-03-12
CA2327775A1 (en)	1999-10-14

Publication	Publication Date	Title
BG64600B1 (bg)	2005-08-31	Кетолиди от класа на 15-членни лактами с антибактериална активност
SI9011409A (en)	1995-10-31	O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
KR100554549B1 (ko)	2006-03-03	9ａ-아잘리드류로부터 유래한 신규한 3,6-헤미케탈
US4833236A (en)	1989-05-23	Erythromycin derivatives
EP1181298B1 (en)	2006-07-19	Novel 8a- and 9a-15-membered lactams
Kurihara et al.	1996	Cladinose analogues of sixteen-membered macrolide antibiotics I. Synthesis of 4-O-alkyl-l-cladinose analogues via glycosylation
BG63164B1 (bg)	2001-05-31	9-n-етенил производни на 9(s)-еритромициламин
CZ20003704A3 (cs)	2001-01-17	15-členné laktamové ketolidy s antibakteriální účinností
HK1036457B (en)	2004-08-20	15-membered lactams ketolides with antibacterial activity
CN1197075A (zh)	1998-10-28	从红霉素衍生的新的断大环内酯类及其制备方法
JP2006507315A (ja)	2006-03-02	９−デオキソ−９−ジヒドロ−９ａ−アザ−９ａ−ホモエリスロマイシンＡ及び５−Ｏ−デソサミニル−９−デオキソ−９−ジヒドロ−９ａ−アザ−９ａ−ホモエリスロノリドＡの置換した９ａ−Ｎ−｛Ｎ’−［４−（スルホニル）フェニルカルバモイル］｝誘導体
MXPA00009875A (es)	2001-11-21	Cetolidos de lactamas de 15 miembros con actividad antibacteriana